학술논문
Results of a survey on the use of rituximab in Japanese pancreas transplant cases / 本邦膵臓移植症例におけるrituximab（遺伝子組換え）に関する使用実態調査の結果—膵移植後rituximab使用4症例の報告—
Document Type
Journal Article
Author
Source
移植 / Japanese Journal of Transplantation. 2021, 56(1):35
Subject
Language
Japanese
ISSN
0578-7947
2188-0034
2188-0034
Abstract
【Results】 Although pancreatic graft biopsies were not performed in any case, kidney graft biopsy was performed in 3 cases for the diagnosis of AMR. After the diagnosis of rejection, two were positive for DSA class II, and two were positive for both DSA class I and II. As a treatment for AMR, one patient received 50 mg/m2 of rituximab, and the other three patients received 200 mg/body. The pancreatic graft prognosis after AMR was graft loss in 3 of the 4 cases. As an adverse event after AMR treatment, antigenemia due to cytomegalovirus (n＝1) and bone marrow suppression (n＝2) were observed as adverse events; however, none of these adverse events was serious and all cases recovered.